FDA warns of progressive multifocal leukoencephalopathy (PML) risk with Tysabri - MPR
Links shared publicly online about this topic.
- 1,730total visits
FDA warns of progressive multifocal leukoencephalopathy (PML) risk with Tysabri - MPR
empr.com —
View full resource at empr.com
Tags: FDA, Tysabri, Biogen Idec
Most Recently Shared on September 22, 2009 at 5:28 pm By:
MPR News: FDA warns of progressive multifocal leukoencephalopathy (PML) risk with Tysabri: The FDA cont.. http://bit.ly/ke2nc
Adcetris (brentuximab vedotin): Drug Safety Communication - Progressive Multifocal Leukoencephalopathy and Pulmonary Toxicity
fda.gov — “New Boxed Warning and Contraindication highlighting these risks added to product labeling.” View full resource at fda.gov
Most Recently Shared on January 13, 2012 at 5:25 pm By:
Ramsey Baghdadi Health Communicator
two new cases of PML with Seattle Genetics' Adcetris: http://t.co/lb13qx7p
Medical News: FDA Updates PML Risk Info for Natalizumab - in Neurology, Multiple Sclerosis from MedPage Today
medpagetoday.com — “As expected, the FDA has approved new label language for the multiple sclerosis drug natalizumab (Tysabri) with additional detail on the risks of progressive multifocal leukoencephalopathy (PML).” View full resource at medpagetoday.com
Most Recently Shared on April 22, 2011 at 8:31 pm By:
Thomas Loarie, Jr Health Advocate
@medpagetoday FDA Updates PML Risk Info for Natalizumab http://bit.ly/i6ZA0J #medical #Health
Medical News: FDA Adds PML Risk to MS Drug Label - in Product Alert, Prescriptions from MedPage Today
medpagetoday.com — “WASHINGTON -- A warning of a risk of progressive multifocal leukoencephalopathy has been added to the label for the multiple sclerosis drug natalizumab (Tysabri), the FDA announced.” View full resource at medpagetoday.com
Most Recently Shared on February 5, 2010 at 10:07 pm By:
FDA Adds PML Risk to MS Drug Label WASHINGTON (MedPage Today) -- A warning of a risk of progressive multifocal leukoe.. http://bit.ly/bkEhX3
Tysabri (Natalizumab): Update of Healthcare Professional Information
fda.gov — “Risk of developing progressive multifocal leukoencephalopathy (PML) increases with increasing duration of exposure to Tysabri.” View full resource at fda.gov
Most Recently Shared on February 5, 2010 at 4:43 pm By:
eyeonfda Pharma and Health Lawyer
FDA MedWatch updates on Tysabri - http://ow.ly/14hlb - PML Risk increases with number of infusions.
New Raptiva Warnings: Risk of PML Brain Disease
usrecallnews.com — “FDA has put a black box warning on the psoriasis drug Raptiva after at least three cases of progressive multifocal leukoencephalopathy (PML). All three have died.” View full resource at usrecallnews.com
Most Recently Shared on March 1, 2009 at 2:34 am By:
New blog post: New Raptiva Warnings: Risk of PML Brain Disease http://tinyurl.com/cx3jr5
Advertisement
